Aadi Bioscience, Inc. is a pharmaceutical company based in the United States that focuses on developing precision therapies for genetically-defined cancers. They have a medium risk rating score of 26.4, with a primary goal of providing transformational therapies for cancer patients with mTOR pathway driver alterations. Aadi Bioscience is dedicated to addressing challenges with pharmacology, drug delivery, safety, and targeting specific disease sites. Their business primarily involves developing and commercializing proprietary therapeutics.